Optimum combination of targeted 131I and total body irradiation for treatment of disseminated cancer

Amin, Amin E.; Wheldon, T. E.; O’Donoghue, Joseph A.; Gaze, Mark; Barrett, Ann

doi:10.1016/0360-3016(94)00497-9

Cited by 4 publications

(3 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The combination of targeted therapy and TBI is currently being tried in the clinic. Amin et al (1995) report on five patients treated with 131 I-labelled mIBG to a whole-body dose of 2 Gy followed by a 12 Gy TBI dose; three of the patients were alive and disease free at 9, 14 and 15 months. This is an example where a theoretical study (Wheldon et al 1991) similar to the one presented in detail here has led directly to a modification in the clinical protocol with encouraging preliminary results.…”

Section: Discussion and Concluding Remarksmentioning

confidence: 99%

Microdosimetry and radiocurability: modelling targeted therapy with -emitters

Nahum

1996

Phys. Med. Biol.

View full text Add to dashboard Cite

Tumour control probability (TCP) is a more relevant quantity than the dose distribution in the target volume for estimating the likely efficacy of any type of radiation therapy, be it external beam or targeted using radionuclides. This paper concentrates on a TCP modelling study, for tumour spheres of different radii assuming a uniform uptake of six different beta emitters (ranging from 67Cu to 90Y or 0.58 to 2.3 MeV in endpoint energy). The dose at varying radii, expressed as a fraction of the equilibrium dose, D beta (R)/Deq, was computed by numerical integration of the point-dose kernel over the sphere volume, and shows clearly the effect of electron disequilibrium for small radii and also at the edges of the spheres. These D beta(R)/Deq were converted into volume-dose distribution V(D) and thence into clonogenic cell numbers, n(D), from which the TCPs for spheres of different radii were computed, for different cumulated activities per unit mass, in megabecquerel hours per gram assuming a clonogenic cell density of 10(8) cm-3 and a tumour-cell radiosensitivity alpha of 1.0 Gy-1. Using V(D) rather than simply the mean dose decreases the TCP at both large and small tumour radii for a given number of megabecquerel hour per gram. Curves of iso-TCP go through a shallow minimum in megabecquerel hour per gram at a tumour radius approximately equal to the maximum beta-particle range. The fall in dose at small radii outweighs the reduction in cell number, making it improbable that micrometastases can be eliminated solely by beta-emitters targeted to the tumour cells. An explicit comparison with external-beam therapy for a fixed number of tumour cells divided into different numbers of spheres further emphasizes the difficulties caused by small tumours in beta-particle targeted therapy. Alternative strategies to overcome these limitations are briefly discussed.

show abstract

Section: Discussion and Concluding Remarksmentioning

confidence: 99%

Microdosimetry and radiocurability: modelling targeted therapy with -emitters

Nahum

1996

Phys. Med. Biol.

View full text Add to dashboard Cite

show abstract

“…1.85 Gy and 17.59 Gy, respectively, are applied. For µ of tumour, values of 0.46 h -1 (Amin et al, 1995) and of 1.28 h -1 (Brenner and Hall, 1991), have been reported, and both values are used for calculations. The pair of radiobiological parameters (α/β =1.85 Gy, and µ=0.46 h -1 ) is used to represent tumours that are sensitive to fractionation and typically also slow-growing, while the second pair of values (α/β =17.59 Gy and µ=1.28 h -1 ) is used to represent highly proliferative tumours which are less sensitive to fractionation.…”

Section: 2analysis Of Fractionated 131 I-mibg Treatment Of Nbmentioning

confidence: 99%

“…For instance, Courdi et al (1992) reported a value of 1.85 Gy for the CHP100 cell line, Holmes et al (1990) gave values of 5.00 Gy for the HX138 cell line and 9.38 Gy for the HX142 cell line, and Marchese et al (1987) reported a value of 17.59 Gy for the SK-N-SH cell line. In Fertil and Malaise (1985), Malaise et al (1987) and Amin et al (1995), NB was included among highly responsive tumours and values of 7.11 Gy, 8.31 Gy and 13.08 Gy were respectively reported. For the purpose of this study, the lowest and the highest α/β values found in the literature, i.e.…”

Section: Analysis Of Fractionated 131 I-mibg Treatment Of Nbmentioning

confidence: 99%

Biologically effective dose in fractionated molecular radiotherapy—application to treatment of neuroblastoma with¹³¹I-mIBG

et al. 2016

View full text Add to dashboard Cite

In this work, the biologically effective dose (BED) is investigated for fractionated molecular radiotherapy (MRT). A formula for the Lea–Catcheside G-factor is derived which takes the possibility of combinations of sub-lethal damage due to radiation from different administrations of activity into account. In contrast to the previous formula, the new G-factor has an explicit dependence on the time interval between administrations. The BED of tumour and liver is analysed in MRT of neuroblastoma with 131I-mIBG, following a common two-administration protocol with a mass-based activity prescription. A BED analysis is also made for modified schedules, when due to local regulations there is a maximum permitted activity for each administration. Modifications include both the simplistic approach of delivering this maximum permitted activity in each of the two administrations, and also the introduction of additional administrations while maintaining the protocol-prescribed total activity. For the cases studied with additional (i.e. more than two) administrations, BED of tumour and liver decreases at most 12% and 29%, respectively. The decrease in BED of the tumour is however modest compared to the two-administration schedule using the maximum permitted activity, where the decrease compared to the original schedule is 47%.

show abstract

Radiobiologic Factors to Consider with Total Marrow Irradiation

Song

Storme

2020

Total Marrow Irradiation

View full text Add to dashboard Cite

Optimum combination of targeted 131I and total body irradiation for treatment of disseminated cancer

Cited by 4 publications

References 18 publications

Microdosimetry and radiocurability: modelling targeted therapy with -emitters

Microdosimetry and radiocurability: modelling targeted therapy with -emitters

Biologically effective dose in fractionated molecular radiotherapy—application to treatment of neuroblastoma with¹³¹I-mIBG

Radiobiologic Factors to Consider with Total Marrow Irradiation

Contact Info

Product

Resources

About

Optimum combination of targeted 131I and total body irradiation for treatment of disseminated cancer

Cited by 4 publications

References 18 publications

Microdosimetry and radiocurability: modelling targeted therapy with -emitters

Microdosimetry and radiocurability: modelling targeted therapy with -emitters

Biologically effective dose in fractionated molecular radiotherapy—application to treatment of neuroblastoma with131I-mIBG

Radiobiologic Factors to Consider with Total Marrow Irradiation

Contact Info

Product

Resources

About

Biologically effective dose in fractionated molecular radiotherapy—application to treatment of neuroblastoma with¹³¹I-mIBG